JXR1951.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, JXR (1951.HK) trades at a P/E of 33.50x, P/B of 0.58x, P/S of 1.90x, and a dividend yield of 1.90%.
Longitudinal percentile comparison: P/E sits at the 33rd percentile over the trailing 10Y window (vs. 86th percentile over 3Y); P/B sits at the 5th percentile over the trailing 10Y window (vs. 12th percentile over 3Y); P/S sits at the 2nd percentile over the trailing 10Y window (vs. 6th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 77th percentile within its industry and the 85th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 8.90%, ranking at the 100th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 28.1 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 8.90% total shareholder yield, 1.90% is paid out as dividends and roughly 7.00% is implied to come from buybacks — both channels are meaningfully in play. JXR operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 1951 · SEHK: 1951 · 1951
Want the full picture on whether JXR (1951.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 33.50 | ||||||
| P/B (MRQ) | 0.58 | ||||||
| P/S (TTM) | 1.90 | ||||||
| Dividend Yield | 1.90% | ||||||
| Buyback + Div Yield | 8.90% |